References
Yellon D, Hausenloy D. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–35.
Gomez L, Li B, Mewton N, Sanchez I, Piot C, Elbaz M, et al. Inhibition of mitochondrial permeability transition pore opening: translation to patients. Cardiovasc Res. 2009;83:226–33.
Hausenloy D, Tsang A, Yellon D. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med. 2005;15:69–75.
Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol. 2009;47:32–40.
Cohn J. The management of chronic heart failure. N Engl J Med. 1996;335:490–8.
Stanley W, Chandler M. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev. 2002;7:115–30.
Keul P, Sattler K, Levkau B. HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev. 2007;12:301–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deshpande, G.P., McCarthy, J., Mardikar, H. et al. Effects of Sphingosine-1-Phosphate on Acute Contractile Heart Failure (ACHF). Cardiovasc Drugs Ther 24, 459–460 (2010). https://doi.org/10.1007/s10557-010-6258-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-010-6258-4